Corebridge Financial Inc. Sells 50 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)

Corebridge Financial Inc. trimmed its holdings in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 2.2% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 2,209 shares of the biopharmaceutical company’s stock after selling 50 shares during the quarter. Corebridge Financial Inc.’s holdings in Alnylam Pharmaceuticals were worth $520,000 at the end of the most recent quarter.

Several other institutional investors also recently bought and sold shares of ALNY. Regeneron Pharmaceuticals Inc. acquired a new position in shares of Alnylam Pharmaceuticals during the 4th quarter valued at about $1,045,822,000. Raymond James Financial Inc. acquired a new stake in Alnylam Pharmaceuticals in the 4th quarter worth approximately $65,295,000. Jennison Associates LLC bought a new stake in Alnylam Pharmaceuticals during the fourth quarter worth approximately $61,160,000. Proficio Capital Partners LLC grew its holdings in Alnylam Pharmaceuticals by 25,929.6% during the fourth quarter. Proficio Capital Partners LLC now owns 193,660 shares of the biopharmaceutical company’s stock valued at $45,570,000 after purchasing an additional 192,916 shares during the last quarter. Finally, Strategic Financial Concepts LLC bought a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at approximately $41,529,000. 92.97% of the stock is currently owned by institutional investors.

Insider Activity

In other news, CEO Yvonne Greenstreet sold 1,213 shares of the firm’s stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $309,521.21. Following the completion of the sale, the chief executive officer now directly owns 81,526 shares in the company, valued at approximately $20,802,989.42. This trade represents a 1.47 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. Also, CMO Pushkal Garg sold 52,592 shares of the company’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the transaction, the chief marketing officer now owns 11,989 shares in the company, valued at approximately $3,416,865. This trade represents a 81.44 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 71,234 shares of company stock worth $19,958,097. Insiders own 1.50% of the company’s stock.

Analysts Set New Price Targets

Several research analysts recently commented on the stock. Chardan Capital reiterated a “buy” rating and issued a $300.00 target price on shares of Alnylam Pharmaceuticals in a report on Friday, March 21st. Morgan Stanley raised their price target on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the company an “equal weight” rating in a research report on Friday, February 14th. Needham & Company LLC reissued a “buy” rating and set a $320.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Friday, March 21st. Stifel Nicolaus lifted their price target on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a “buy” rating in a research report on Monday, March 31st. Finally, Wells Fargo & Company increased their price objective on Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the company an “equal weight” rating in a research report on Friday, March 21st. One analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $316.25.

Alnylam Pharmaceuticals Stock Performance

Shares of NASDAQ:ALNY opened at $224.32 on Wednesday. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. The business’s fifty day moving average price is $256.07 and its two-hundred day moving average price is $259.24. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $304.39. The stock has a market capitalization of $29.18 billion, a price-to-earnings ratio of -103.37 and a beta of 0.30.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, analysts predict that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.